Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Mexico
  4. Mexican Stock Exchange
  5. Genomma Lab Internacional, S.A.B. de C.V.
  6. News
  7. Summary
    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

(LAB B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genomma Lab Internacional B de C : 3Q-2021 Earnings Call Advisory

10/14/2021 | 07:12pm EST

Investor Relations

T. +52 (55) 5081 0000 investor.relations@genommalab.com

Genomma Lab Internacional S.A.B. DE C.V.

Third Quarter 2021 Earnings Call

Presenters:

Mr. Jorge Luis Brake, Chief Executive Officer

Mr. Antonio Zamora, Chief Financial Officer

Date:

Thursday, October 28, 2021

Time:

11:00 a.m. ET / 10:00 a.m. CST (Mexico City Time)

Dial-in:

+1 877-407-0784 (U.S.)

+1 201-689-8560 (International)

If you would prefer to receive a call rather than dialing in, please register via the

following link. Please use this option 10-15 minutes prior to conference call start

time: Call Me Link

Participants who do not wish to be interrupted to have their information gathered may have

provider dial out to them by clicking on the above link, filling in the information, and pressing the

green phone button at the bottom. The phone number provided will be automatically called and

connected to the conference without any interruption to the participant. (Please note: Participants

will be joined directly to the conference and will hear hold music until the call begins. No

confirmation message will be played when joined.)

Webcast:

Third Quarter 2021 Results

Replay:

+1 844-512-2921 (U.S.)

+1 412-317-6671 (International)

Replay ID: 13723981

**Available until November 4, 2021

Note:

Genomma Lab will report Third Quarter 2021 Earnings Release on Wednesday,

October 27, 2021 after the Mexican Market (BMV) close.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

www.genommalab.com/inversionistas/

1

Disclaimer

Genomma Lab International SAB de CV published this content on 14 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 October 2021 23:11:02 UTC.


ę Publicnow 2021
All news about GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
11/18GENOMMA LAB INTERNACIONAL B DE C : Oramed and Genomma Lab Internacional Announce Joint Ven..
PU
11/18Oramed Pharmaceuticals Inc. and Genomma Lab Internacional, S.A.B. de C.V. Announces Joi..
CI
10/28Genomma Lab Internacional to Seek Acquisitions
CI
10/28TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
10/27Genomma Lab Q3 2021 Earnings Release
PU
10/27Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarte..
CI
10/14GENOMMA LAB INTERNACIONAL B DE C : 3Q-2021 Earnings Call Advisory
PU
09/07GENOMMA LAB INTERNACIONAL B DE C : Receives Good Manufacturing Practices (GMP) Certificati..
PU
08/04GENOMMA LAB INTERNACIONAL B DE C : External Auditor Ratification
PU
07/28GENOMMA LAB INTERNACIONAL B DE C : Q2 2021 Earnings Release
PU
More news
Financials
Sales 2021 14 705 M 676 M 676 M
Net income 2021 1 616 M 74,3 M 74,3 M
Net Debt 2021 3 750 M 172 M 172 M
P/E ratio 2021 11,8x
Yield 2021 1,58%
Capitalization 18 173 M 830 M 836 M
EV / Sales 2021 1,49x
EV / Sales 2022 1,33x
Nbr of Employees 2 067
Free-Float 68,2%
Chart GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Duration : Period :
Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 18,06 MXN
Average target price 26,13 MXN
Spread / Average Target 44,7%
EPS Revisions
Managers and Directors
Jorge Luis Brake Valderrama Chief Executive Officer
Antonio Zamora Galland Vice President-Administration & Finance
Rodrigo Alonso Herrera Aspra Chairman
Marco Sparvieri Chief Operating Officer & Executive Vice President
Juan Alonso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.-4.14%830
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049